Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue: +93.9%
EPS: −120.0%
Free cash flow: +13.4%
Total debt: +57.4%

Quarter to June 2026, against a year earlier

Revenue growth 3 yrs

8.67 0.66 +8.24%

Follow IBRX

Alert me

Market cap: $8.5B
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 4/9
Altman Z: −10.16
Beneish M: 4.57
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

ImmunityBio, Inc. (IBRX) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Product revenue, net	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

ImmunityBio, Inc. (IBRX) revenue by segment, product and region

Stockrow Weekly